Sotera Health Co (Sotera Health Co) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Sotera Health Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sotera Health Co is: High Risk: High uncertainty.

Competitive Comparison of Sotera Health Co's Risk Assessment

For the Diagnostics & Research subindustry, Sotera Health Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sotera Health Co's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sotera Health Co's Risk Assessment falls into.

Sotera Health Co (NAS:SHC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sotera Health Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Sotera Health Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sotera Health Co (Sotera Health Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Sotera Health Co (NAS:SHC) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

9100 South Hills Boulevard, Suite 300, Broadview Heights, OH, USA, 44147

Website

https://investors.soterahealth.com

Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and advanced applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe, and other regions.

Executives

Jonathan M. Lyons	officer: Sr. Vice President, CFO	9100 SOUTH HILLS BLVD., SUITE 300, BROADVIEW HEIGHTS OH 44147
Robert Brown Knauss	director	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Alexander Dimitrief	officer: SVP, General Counsel and Sec.	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Michael F Biehl	officer: Interim CFO	5885 LANDBROOK DRIVE SUITE 205, CLEVELAND OH 44124
Terry Hammons	officer: SVP, GC and Secretary	C/O SIMPSON MANUFACTURING CO., INC., 5956 W LAS POSITAS BLVD, PLEASANTON CA 94588
Michael P Rutz	officer: President of Sterigenics	8755 WEST HIGGINS ROAD, SUITE 500, CHICAGO IL 60631
Wp Xi Partners, L.p.	director, 10 percent owner	C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, 450 LEXINGTON AVENUE NY 10017
Warburg Pincus & Co.	director, 10 percent owner	450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147
Gtcr Fund Xi/a Lp	director, 10 percent owner	300 NORTH LASALLE STREET, SUITE 5600, CHICAGO IL 60654
Matthew J Klaben	officer: SVP, GC and Secretary	ONE INFINITY CORPORATE CENTRE DRIVE, SUITE 300, GARFIELD HEIGHTS OH 44125
Petras Michael B. Jr.	director, officer: Chairman & CEO	9100 SOUTH HILLS BLVD, SUITE 300, BROADVIEW HEIGHTS OH 44147
Stephanie Geveda	director	450 LEXINGTON AVENUE, C/O WARBURG PINCUS LLC, NEW YORK NY 10017
Sean Laurence Cunningham	director	300 N. LASALLE SUITE 5600, CHICAGO IL 60654
Scott J. Leffler	officer: CFO and Treasurer	C/O CLOVER HEALTH INVESTMENTS, CORP., 3401 MALLORY LANE, SUITE 210, FRANKLIN TN 37067